How much is the latest price of dasatinib in 2025?

Dasatinib (Dasatinib) is a targeted drug mainly used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It inhibits the activity of BCR-ABL tyrosine kinase and prevents the proliferation of tumor cells, thus exerting anti-cancer effects. In recent years, as the incidence of chronic myelogenous leukemia has gradually increased, the clinical application of dasatinib has become more and more widespread.

In China, dasatinib has been successfully launched and included in medical insurance, bringing good news to many patients. However, the reimbursement policy stipulates that only patients who meet certain conditions can receive corresponding reimbursement. This policy aims to ensure the rational allocation of resources while also encouraging patients to receive standardized treatment under the guidance of doctors. Common specifications of dasatinib include50mg and 20mg. Each box contains 60 tablets, and the price is about 10,000 yuan. Although this price is still a high burden for many patients, medical insurance coverage can alleviate this financial pressure to a certain extent.

Compared with the Chinese market, the price of dasatinib in overseas markets is generally higher, usually reaching more than 10,000 US dollars. This price difference reflects the impact of different countries' pricing strategies on drugs as well as market demand. In addition, some generic drugs of dasatinib have appeared on the overseas market. The ingredients of these generic drugs are very close to the original drugs and their efficacy is roughly the same. Pharmaceutical companies in India and Bangladesh are major generic drug manufacturers. They have adopted a more flexible pricing strategy, so that each box of generic dasatinib may be sold for only a few hundred yuan. This price can not only meet the treatment needs of patients, but also make the drug more accessible.

Overall, the launch of dasatinib as an effective treatment for chronic myeloid leukemia and acute lymphoblastic leukemia provides new hope for patients.

Reference materials:https://go.drugbank.com/drugs/DB01254